SALT LAKE CITY, Utah, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), today announced that management will be presenting at Sidoti & Company’s Year End Virtual Investor Conference, held December 10-11, 2025. Sidoti's Year End Virtual Investor ConferenceDates: December 10-11, 2025Presentation Date and Time: Wednesday, December 10, 2025 at 3:15 P.M. ETWebcast: https://sidoti.zoom.us/webinar/register/WN_O_OnAvXpQki63dk_9JbUYw To schedule a one-on-one meetin ...

Core Insights - Becton, Dickinson and Company (BDX) is a leading player in the medical supplies and devices sector, with a market capitalization of $55.4 billion, focusing on advancing medical research, diagnostics, and infection prevention [1][2] Company Overview - BDX is categorized as a large-cap stock, reflecting its significant size and influence in the medical instruments and supplies industry [2] - The company boasts a strong global brand, extensive distribution network, and a diverse product portfolio, which are key to its competitive advantage [2] - BDX's growth is driven by its commitment to innovation, substantial R&D investments, and strategic acquisitions, alongside a robust manufacturing and supply chain [2] Stock Performance - BDX's stock has experienced a decline of 23% from its 52-week high of $251.99, reached on February 3 [3] - Over the past three months, BDX's stock gained 1.5%, underperforming the Nasdaq Composite, which saw a 7.7% increase [3] - Year-to-date, BDX shares have fallen 14.5%, and over the past 52 weeks, they have decreased by 12.6%, significantly lagging behind the Nasdaq's YTD gains of 21% and 22.6% [4] Recent Financial Performance - In its Q4 results, BDX reported an adjusted EPS of $3.96, surpassing Wall Street's expectations of $3.92, with revenue of $5.9 billion meeting forecasts [5] - The company anticipates full-year adjusted EPS to be in the range of $14.75 to $15.05 [5] Competitive Landscape - BDX's competitor, Solventum Corporation (SOLV), has outperformed BDX, with a 17.6% gain over the past 52 weeks and a 29.1% increase year-to-date [6]

Core Insights - Hinde Group's third-quarter 2025 investor letter reported a gross return of 14.37% and a net return of 13.93%, outperforming the S&P 500 Total Return of 8.12% [1] - The year-to-date return for the fund was 36.44% (gross) and 34.91% (net), significantly higher than the index's 14.83% [1] - The generative AI investment boom is identified as a key factor contributing to economic stability and stock market optimism despite ongoing challenges [1] Company Highlights - Becton, Dickinson and Company (NYSE: BDX) was highlighted as a significant stock in Hinde Group's investor letter [2] - BDX's one-month return was 1.07%, but it experienced a decline of 13.86% over the past 52 weeks [2] - As of November 14, 2025, BDX's stock closed at $193.04 per share, with a market capitalization of $55.33 billion [2] Investment Position - Hinde Group initiated a long position in Becton, Dickinson and Company (NYSE: BDX) during the third quarter of 2025, marking it as a special situation investment and the first new position since 2022 [3]

Market Overview - The US equity market experienced a rally in the third quarter of 2025, with the S&P 500 Index increasing by 8.12% [1] - Bonds also performed well, with the Bloomberg U.S. Aggregate Bond Index rising by 2.03% during the same period [1] Performance Analysis - The composite return for the quarter was 7.22% gross of fees and 7.10% net of fees, which underperformed the S&P 500 Index's gain of 8.12% [1] - The underperformance of the strategy was attributed to security selection [1] Company Focus: Becton, Dickinson and Company (NYSE: BDX) - Becton, Dickinson and Company is a healthcare company involved in the development and manufacturing of medical supplies and diagnostic products [2] - The stock had a one-month return of 1.07% but lost 13.86% of its value over the past 52 weeks, closing at $193.04 per share with a market capitalization of $55.33 billion on November 14, 2025 [2] Recent Developments - The company faced challenges due to recent fiscal earnings results, which were negatively impacted by funding cuts from the National Institutes of Health (NIH) [3] - Becton, Dickinson and Company lowered its forward earnings and revenue guidance, citing weaknesses in biosciences R&D funding and the effects of tariffs [3] - The company is attempting to divest its Biosciences and Diagnostic Solutions divisions, but there are concerns about achieving optimal value due to the cyclical downturn in these sectors [3] Investment Sentiment - Becton, Dickinson and Company was held by 58 hedge fund portfolios at the end of the second quarter of 2025, an increase from 54 in the previous quarter [4] - Despite its potential, analysts suggest that certain AI stocks may offer better upside potential and lower downside risk compared to Becton, Dickinson and Company [4] - The company's revenue grew by 7% to $5.9 billion in the fiscal fourth quarter of 2025, with a 3.9% organic growth rate [4]

Core Viewpoint - LeMaitre Vascular, Inc. is actively engaging with investors through participation in three upcoming healthcare conferences, highlighting its commitment to investor relations and market presence [1]. Company Participation in Conferences - LeMaitre Vascular will present at the following investor conferences: - Jefferies London Healthcare Conference on November 18, 2025, with CFO Dorian LeBlanc presenting at 8:00 AM GMT [2]. - Wolfe Research 7th Annual Healthcare Conference on November 19, 2025, with President David Roberts presenting at 10:40 AM ET [2]. - Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, with CFO Dorian LeBlanc presenting at 3:20 PM ET [2]. Company Overview - LeMaitre Vascular specializes in devices, implants, and services for treating peripheral vascular disease, which affects over 200 million people globally [2]. - The company develops, manufactures, and markets both disposable and implantable vascular devices tailored for vascular surgeons [2].

Core Insights - Danaher Corporation (NYSE:DHR) is considered one of the best medical stocks to buy currently, despite a recent price target reduction by BofA from $230 to $220 while maintaining a Buy rating [1] - There are signs of stabilization and improvement in certain areas of Life Sciences and Diagnostic Tools, but there are also pockets of uncertainty and softness observed over the past year [2] - BofA anticipates that these trends will continue for at least the next few quarters, leading to a more gradual return to normalcy in the market [2] Company Overview - Danaher Corporation designs, manufactures, and markets a wide range of professional, medical, industrial, and commercial products and services, making it a significant player in the diagnostics sector [2] - The company operates through several segments, including Diagnostics, Biotechnology, Life Sciences, and Environmental and Applied Solutions [2] Segment Details - The Biotechnology segment provides various equipment and consumables for biological medicines [3] - The Life Diagnostics segment offers clinical instruments, devices, consumables, and services for diagnosing and treating diseases [3]

Group 1 - Microsoft Corp. is recognized as one of the best ESG stocks to buy currently, according to hedge funds [1] - OpenAI is nearing a governance overhaul that will transition it into a conventional for-profit structure, while its nonprofit arm will receive an equity stake of at least $100 billion [1][2] - The potential equity stake could represent approximately 20% ownership if OpenAI's valuation reaches $500 billion through an employee share sale, solidifying its position as the world's most valuable startup [2] Group 2 - The restructuring follows extensive negotiations with Microsoft, which is OpenAI's largest backer, and is crucial for advancing the restructuring process [3] - This deal allows Microsoft to maintain deep integration rights for OpenAI's tools, alleviating investor concerns and positively impacting share prices [3] - The restructuring plans were initially discussed by OpenAI in early May, indicating significant implications for both OpenAI and Microsoft [4]

Group 1 - Jim Cramer acknowledged his previous negative call on Alphabet Inc. stock, reflecting on its price movement from around $140 to $234, indicating that the stock was never truly expensive despite concerns about regulatory actions [1] - The recent judicial ruling suggested that Alphabet was no longer considered a monopolist, which contributed to the stock's rise without significant market apprehension [1] - Cramer emphasized that the stock's increase occurred without remorse from those who previously deemed it dangerous, highlighting a shift in market sentiment towards Alphabet [1] Group 2 - Alphabet Inc. offers a wide range of platforms and services, including search, YouTube, Android, Google Play, and cloud-based AI solutions, alongside investments in healthcare and technology ventures through its Other Bets segment [2] - While Alphabet is recognized for its potential as an investment, there are AI stocks perceived to have greater upside potential and lower downside risk, suggesting a competitive landscape in the AI sector [3]

All four of the devices will be available to preorder on Friday and will be available on September 19. https://t.co/Wf96VYuppT ...

Our portfolio project, @combinderio, has done a great campaign!They've succeeded in having:- 500+ pre-orders- 934 total devices connected post-campaignGreat progress for such an early project, very happy to be on board with @MNCapital_vc!Combinder (@combinderio):The Source Awakens... Final Results!Our campaign with @shelly_IoT and @peaq is complete and the numbers are in.From connected devices to top regions, here’s how the community made it happen: https://t.co/c09p2X4znz ...